In real-world use, Kayfanda (odevixibat) — available under the brand name Bylvay in the U.S. — lowered blood…
Articles by Marisa Wexler, MS
Biochemical crosstalk between the body’s own cells and microbes living in the intestines helps regulate the accumulation of fat in…
A molecular system controlled by a protein called FBP1 is responsible for how liver cells damaged by MASH — fully,…
Alagille syndrome may cause problems with skull development that can put abnormal pressure on the brain, and screening babies…
Tobevibart and elebsiran, an experimental treatment combination that Vir Biotechnology is developing for chronic hepatitis D, has been…
A branch of the European Medicines Agency (EMA) has recommended that Gilead Sciences’ oral therapy seladelpar be approved in…
Cholestasis is a common complication among critically ill people with COVID 19-associated acute respiratory distress syndrome (ARDS), a life-threatening…
Kidney and blood vessel problems are common in people with Alagille syndrome, and while these often cause few to…
After 2.5 years of Livdelzi (seladelpar) treatment, more than 4 in 5 adults with primary biliary cholangitis (PBC)…
Nearly 1.5 years of treatment with Bylvay (odevixibat) effectively reduces itching and liver damage markers, and improves growth and…